Observational comparison of the overall survival of patients receiving Orca-T versus PTCy
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2025-01-23
Просмотров: 253
Описание:
Caspian Oliai, MD, MS, University of California, Los Angeles, CA, comments on the long-term follow-up results of a Phase Ib trial (NCT04013685) investigating Orca-T, a high-precision immune therapy, as a myeloablative conditioning strategy in patients with advanced hematological malignancies. Dr Oliai also highlights the findings of a retrospective observational study, which compared the outcomes of a subset of patients from this Phase Ib trial to a similar subset of patients from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry who received post-transplantation cyclophosphamide (PTCy). This analysis highlighted the superior overall survival (OS) seen with Orca-T compared to PTCy. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
